Antibody to influenza virus neuraminidase: An independent correlate of protection

Journal of Infectious Diseases

Volumn 212, Issue 8, 2015, Pages 1191-1199

  Monto, Arnold S ^a   Petrie, Joshua G ^a   Cross, Rachel T ^a   Johnson, Emileigh ^a   Liu, Merry ^b   Zhong, Weimin ^b   Levine, Min ^b   Katz, Jacqueline M ^b   Ohmit, Suzanne E ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

clinical trial; hemagglutinin; immune correlates; influenza; influenza vaccine; neuraminidase; serologic assays; vaccine response

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; VIRUS SIALIDASE; IMMUNOGLOBULIN; INACTIVATED VACCINE; LIVE VACCINE; SIALIDASE; VIRUS ANTIBODY; VIRUS HEMAGGLUTININ;

ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; DRUG EFFICACY; DRUG RESPONSE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; INFLUENZA A (H3N2); INFLUENZA VACCINATION; MICRONEUTRALIZATION ASSAY; NEURAMINIDASE INHIBITION ASSAY; NORMAL HUMAN; PRIORITY JOURNAL; SEROLOGY; VIRUS NEUTRALIZATION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; CONTROLLED STUDY; ENZYMOLOGY; FEMALE; IMMUNOLOGY; INFLUENZA, HUMAN; MALE; MIDDLE AGED; ORTHOMYXOVIRIDAE; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS, VIRAL; HUMANS; IMMUNOGLOBULINS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEURAMINIDASE; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE; VACCINATION; VACCINES, ATTENUATED; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84939835607     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv195     Document Type: Article

References (23)

1. Salk JE, Menke WJ, Francis T A clinical, epidemiological and immunological evaluation op vaccination against epidemic influenza. Am J Epidem. 1945; 42: 57-93
2. Meiklejohn G, Kempe CH, Thalman WG, Lennette EH. Evaluation of monovalent influenza vaccines ii. Observations during an influenza A-prime epidemic. Am J Hygiene. 1952; 55: 12-21
3. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70: 767-77
4. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull. 1979; 35: 69-75
5. The European Agency for the Evaluaton of Medicinal Products Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines. CPMP/BWP/214/.96. London, United Kingdom: European Medicines Agency, 1997
6. Stephenson I, Heath A, Major D, et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis. 2009; 15: 1252-9
7. Reber A, Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Exp Rev Vacc. 2013; 12: 519-36
8. Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis. 2011; 203: 1309-15
9. Marcelin G, Sandbulte MR, Webby RJ. Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. Rev Med Virol. 2012; 22: 267-79
10. Aymard-Henry M, Coleman MT, Dowdle WR, Laver WG, Schild GC, Webster RG. Influenza virus neuraminidase and neuraminidase inhibition test procedures. Bull World Health Organ. 1973; 48: 199-202
11. Monto AS, Kendal AP. Effect of neuraminidase antibody on Hong Kong influenza. Lancet. 1973; 1: 623-5
12. Sandbulte MR, Gao J, Straight TM, EichelbergerMC. Aminiaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza Other Respir Viruses. 2009; 3: 233-40
13. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis. 2011; 204: 1879-85
14. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009; 361: 1260-7
15. Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Exp Rev Vacc. 2011; 9: 669-83
16. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Micro. 1999; 37: 937-43
17. Couzens L, Gao J, Westgeest K, et al. An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera. J Virol Meth. 2014; 210: 7-14
18. Johansson BE, Cox MMJ. Influenza viral neuraminidase: the forgotten antigen. Exp Rev Vacc. 2011; 10: 1683-95
19. Wood JM, Levandowski RA. The influenza vaccine licensing process. Vaccine. 2003; 21: 1786-8
20. Couch RB, Atmar RL, Keitel WA, et al. Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine. 2012; 31: 190-5
21. Johansson BE, Grajower B, Kilbourne ED. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine. 1993; 11: 1037-9
22. Couch RB, Atmar RL, Franco LM, et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis. 2013; 207: 974-81
23. Sultana I, Yang K, Getie-Kebtie M, et al. Stability of neuraminidase in inactivated influenza vaccines. Vaccine. 2014; 32: 2225-30